Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML.

Subgroup analysis indicated a significant benefit of post-HCT gilteritinib for participants in North America but no benefit for those in Europe or Asia.

亚组分析表明，北美地区的参与者在造血干细胞移植（HCT）后使用吉列替尼有显著益处，但在欧洲或亚洲的参与者中则没有这种益处。

We conducted a post hoc analysis of the data focusing on the time from AML diagnosis to HCT, pre-HCT FLT3 inhibitor use, and FLT3-ITD measurable residual disease (MRD).

我们对数据进行了事后分析，重点关注从AML诊断到HCT的时间、HCT前使用FLT3抑制剂的情况以及FLT3-ITD可测量的残留疾病（MRD）。

Participants who underwent transplantation <120 days from AML diagnosis and/or those treated with FLT3 inhibition before HCT were more likely to have improved survival from post-HCT gilteritinib.

在AML诊断后120天内进行移植的参与者，以及/或在HCT前接受FLT3抑制治疗的参与者，更有可能从HCT后使用吉列替尼中获得生存改善。

Pre-HCT MRD levels were higher (P = .001) in participants who underwent transplantation within 120 days from diagnosis and in those treated with an FLT3 inhibitor before HCT and underwent transplantation within 120 days (P = .008).

在诊断后120天内进行移植的参与者以及在HCT前接受FLT3抑制治疗并在120天内进行移植的参与者的HCT前MRD水平较高（P = .001），而在HCT前接受FLT3抑制治疗并在120天内进行移植的参与者的MRD水平也较高（P = .008）。

Pre-HCT MRD was dependent on both FLT3 inhibitor use and time to HCT, because participants treated with successive courses of chemotherapy + FLT3 inhibition had successively lower MRD by the time of HCT.

HCT前的MRD水平取决于FLT3抑制剂的使用和HCT的时间，因为接受化疗+FLT3抑制治疗连续疗程的参与者在HCT时的MRD水平逐渐降低。

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibitor use both appeared to affect MRD levels immediately before HCT, and geographic differences in these 2 practice patterns likely accounted for the observed regional differences in benefit from post-HCT gilteritinib.

从AML诊断到HCT的时间以及HCT前使用FLT3抑制剂的情况似乎都影响了HCT前的MRD水平，这两种实践模式的地理差异可能解释了观察到的HCT后吉列替尼治疗的地区差异益处。

Increasing the number of courses of treatment before HCT may lower MRD sufficiently to eliminate the need for post-HCT inhibition, but with a presumed risk of some patients experiencing early progression.

增加HCT前的治疗疗程数量可能会降低MRD，足以消除HCT后抑制的需要，但可能会有一些患者经历早期进展的风险。

This trial was registered at www.clinicaltrials.gov as #NCT02997202.

这项试验已在www.clinicaltrials.gov上注册，注册号为#NCT02997202。